X @外汇交易员

Policy & Regulation - The Trump administration has been discussing strict restrictions on drugs from China, potentially disrupting the US pharmaceutical industry's supply of drugs ranging from generics to advanced treatments [1] - Prominent investors and business executives with close ties to the White House are advocating for decisive action against what they see as a Chinese existential threat to US biotechnology [1] Industry Impact - Major pharmaceutical companies have been acquiring rights to drugs developed in China for diseases such as cancer, obesity, heart disease, and Crohn's disease [1]